SciDEX
Main
🏠Dashboard🔬Analyses📈Exchange🏛The Agora🗣Debates🔍Research Gaps⚖Compare
Knowledge
📖Wiki🕸Knowledge Graph🗺Atlas📦Artifacts🧬Protein Designs📄Papers📓Notebooks🔎Search
System
🏛Senate⚔Quests💰Resources🔨Forge🤖Agents🚦Status📑Docs
Info
ℹHow it Works🎨Pitch⭐Showcase📽Demo
📖

PET Imaging for Neurodegenerative Diseases

wiki page Created: 2026-04-02 13:40:08 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-technologies-pet-imaging
Related Entities
technologies-pet-imaging
Metadata
slugtechnologies-pet-imaging
entity_typetechnology
kg_node_idNone
Linked Artifacts (314)
mentions🧫GWAS of plasma pTau217 in East Asian cohort70%
mentions🧫KEEPS Continuation: Long-term effects of menopausal hormone 70%
mentions🧫s:** - Compare brain penetration in FcRn+/+ vs FcRn-/- mice 70%
mentions🧫s:** - Biochemical binding assays measuring PROTAC selectivi70%
mentions🧫CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs 70%
mentions🧫4R-Tau Targeting Therapies for PSP and CBS70%
mentions🧫AAV-LRRK2 IND-Enabling Study Design70%
mentions🧫AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Posi70%
mentions🧫Alpha-Synuclein SAA Kinetics Study — Biological Staging Back70%
mentions🧫Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio70%
mentions🧫Computational Modeling of Alpha-Synuclein Propagation in PD70%
mentions🧫Basic Mechanism: Membrane-Driven Alpha-Synuclein Nucleation70%
mentions🧫Alpha-Synuclein Seed Amplification Assay Validation70%
mentions🧫Alpha-Synuclein Spreading Mechanism — Prion-Like Propagation70%
mentions🧫Metabolic Pathway-Targeted Therapy in ALS70%
mentions🧫ALS Progression Rate Heterogeneity — mechanism and biomarker70%
mentions🧫ALS Regional Onset and Spread: Network-Level Staging Model70%
mentions🧫Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk70%
mentions🧫Why Does Amyloid Removal Only Slow Decline 27%? — Mechanisti70%
mentions🧫Mechanism: Why Does Amyloid Removal Only Slow Decline 27%?70%
mentions🧫Animal Model Comparison for Neurodegenerative Disease Therap70%
mentions🧫Anti-Tau Immunotherapy Dosing Optimization70%
mentions🧫Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri70%
mentions🧫Antiviral Therapy Trial for Parkinson's Disease70%
mentions🧫Astrocyte Ferritin Iron Metabolism Dysfunction in Parkinson&70%
mentions🧫Experiment: Autoimmune Hypothesis Testing in AD70%
mentions🧫Autophagy Enhancement Drug Screening for Neurodegeneration70%
mentions🧫Axonal Transport Dysfunction Validation in Parkinson's 70%
mentions🧫Biomarker-Guided Sequential Therapy Selection in Alzheimer&#70%
mentions🧫Blood-Based Biomarker Panel for Early AD Detection70%
mentions🧫Blood Biomarker vs Tau PET for Treatment Monitoring70%
mentions🧫tACS Connectivity Trial in Early Alzheimer's70%
mentions🧫Brain Connectivity-Targeted tACS Trial in Early AD70%
mentions🧫Brainstem Circuit Modulation for PSP70%
mentions🧫Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT70%
mentions🧫C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study70%
mentions🧫Experimental: CAAR-T Cell Therapy for Autoantibody-Mediated 70%
mentions🧫cGAS-STING Pathway Validation Study in Parkinson's Dise70%
mentions🧫Chaperone-Mediated Autophagy Dysfunction in PD - Experiment 70%
mentions🧫Cognitive Reserve Mechanisms in Alzheimer's Disease — M70%
mentions🧫Combination Therapy Sequencing in Parkinson's Disease70%
mentions🧫CRISPR Gene Correction Approaches for CBS/PSP70%
mentions🧫Cholinergic System Dysfunction in DLB — Mechanisms and Thera70%
mentions🧫DLB Cognitive Fluctuation Mechanism Experiment70%
mentions🧫Genetic Risk Modifiers in DLB Phenotype70%
mentions🧫Tau Co-Pathology in DLB Clinical Heterogeneity70%
mentions🧫DLB Treatment Response Biomarkers — Predicting Cholinesteras70%
mentions🧫DNA Damage Repair Deficiency Validation Study in Parkinson&#70%
mentions🧫Mechanism: Selective Vulnerability of Dopaminergic Neurons i70%
mentions🧫Down Syndrome Alzheimer's Disease: Mechanisms and Thera70%
mentions🧫Endocannabinoid System Dysfunction Validation in Parkinson&#70%
mentions🧫Environmental Exposure Causal Attribution in ALS — Experimen70%
mentions🧫Epigenetic Clocks in Neurodegeneration — Causal Drivers or P70%
mentions🧫Epigenetic Dysregulation in Huntington's Disease — Ther70%
mentions🧫Epigenetic Dysregulation Validation in Parkinson's Dise70%
mentions🧫Epigenetic Regulation Dysfunction in Alzheimer's and Pa70%
mentions🧫ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De70%
mentions🧫Exercise-BDNF-Mitophagy Biomarker Study in PD70%
mentions🧫Experiment Index70%
mentions🧫Ferroptosis Validation in Parkinson's Disease70%
mentions🧫Frontal and Temporal Lobe Selective Vulnerability in FTD — M70%
mentions🧫FTD Microglia Role: Protective vs Destructive Mechanism Stud70%
mentions🧫FTLD-Tau vs FTLD-TDP In Vivo Biomarker Differentiation70%
mentions🧫FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio70%
mentions🧫Gap Junction Dysfunction Validation in Parkinson's Dise70%
mentions🧫GLP-1 Agonist Neuroprotection Mechanism in PD70%
mentions🧫GLP-1 Agonist Responder Prediction Study — Precision Medicin70%
mentions🧫Glymphatic-Circadian Axis Enhancement Therapy for Parkinson&70%
mentions🧫Gut-Brain Axis Pathogenesis in Parkinson's Disease — Me70%
mentions🧫Iron Dyshomeostasis in MSA Pathogenesis Experiment70%
mentions🧫Levodopa-Induced Dyskinesias Mechanism — Experiment Design70%
mentions🧫Levodopa Response Determinants in PSP — Biomarker-Guided Pre70%
mentions🧫Cytochrome Therapeutics70%
mentions🧫Lipid Droplet-Lysosome Axis Therapeutic Testing in Parkinson70%
mentions🧫AAV-LRRK2 Gene Therapy IND-Enabling Study Design70%
mentions🧫LRRK2/GBA Mutation Carrier Resilience — Why Some Carriers Ne70%
mentions🧫Macroautophagy Dysfunction in PD - Experiment Design70%
mentions🧫Validate Mitochondria-Lysosome Contact Site Dysfunction in P70%
mentions🧫Validation: Membrane-Nucleation in iPSC Neurons70%
mentions🧫Metabolic Syndrome-Parkinson's Disease Axis Clinical Tr70%
mentions🧫Metal Ion Homeostasis Dysregulation in Alzheimer's Dise70%
mentions🧫Experiment Design: Metal Ion-Synuclein-Mitochondria Axis in 70%
mentions🧫Mutant Huntingtin (mHTT) Clearance Mechanisms — Therapeutic 70%
mentions🧫Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag70%
mentions🧫Microbiome-Gut Barrier Signatures in ALS — Experiment Design70%
mentions🧫Microbiome-Gut-Brain Axis in Alzheimer's Disease — mech70%
mentions🧫Microglial Aging and Immune Memory in Neurodegeneration — Tr70%
mentions🧫Microglial Contributions to Huntington's Disease Pathog70%
mentions🧫Migraine Cortical Hyperexcitability and Alzheimer's Dis70%
mentions🧫Mixed Pathology Effects on Parkinson's Disease Progress70%
mentions🧫MLCS Quantification in Parkinson's Disease70%
mentions🧫Experiment: Multi-Ethnic PD GWAS70%
mentions🧫Multiscale Computational Modeling of Protein Aggregation Kin70%
mentions🧫N-of-1 Clinical Trial Design for CBS/PSP70%
mentions🧫Neural Oscillation Dysfunction Validation in Parkinson'70%
mentions🧫Neural Stem Cell Therapy for Alzheimer's Disease70%
mentions🧫NLRP3 Inflammasome Validation Study in Parkinson's Dise70%
mentions🧫Non-Dopaminergic Neurotransmitter Degeneration in PD - Exper70%
mentions🧫Non-Motor Symptom Progression in Parkinson's Disease — 70%
mentions🧫Normal Aging to Alzheimer's Disease Transition Trigger 70%
mentions🧫CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs 70%
mentions🧫NPH Glymphatic System Interaction Experiment70%
mentions🧫Oligodendrocyte-Myelin Dysfunction Validation in Parkinson&#70%
mentions🧫Parkinson's Disease Subtype Classification — Precision 70%
mentions🧫Peroxisomal Dysfunction Validation in Parkinson's Disea70%
mentions🧫Peroxisome Dysfunction Validation in Parkinson's Diseas70%
mentions🧫Pre-Symptomatic Tau Detection in MAPT Mutation Carriers70%
mentions🧫Presymptomatic GRN Carrier Intervention Timing — Biomarker-G70%
mentions🧫Pre-Symptomatic Detection and Intervention Timing in Genetic70%
mentions🧫Prion Strain Diversity and Selective Vulnerability in CJD70%
mentions🧫Prodromal Parkinson's Disease Biomarker Development — E70%
mentions🧫Progranulin Replacement Therapy for FTD — Vector Development70%
mentions🧫Mechanism: Progranulin Loss and TDP-43 Pathology in FTD70%
mentions🧫Proteasome-Ubiquitin System Dysfunction Validation in Parkin70%
mentions🧫PSP and CBS Biomarker Validation Study70%
mentions🧫Purinergic Signaling Dysfunction Validation in Parkinson70%
mentions🧫Regulated Necrosis Validation Study in Parkinson's Dise70%
mentions🧫Spinocerebellar Ataxia (SCA) Disease-Modifying Therapy Devel70%
mentions🧫SCFA-Mediated Neuroinflammation in Alzheimer's Disease70%
mentions🧫Experiment Scoring Methodology70%
mentions🧫Selective Neuronal Vulnerability to Aging — Mapping Why Spec70%
mentions🧫Senolytic Therapy (D+Q) Phase IIa Trial in Early Alzheimer&#70%
mentions🧫Sex Differences in Alzheimer's Disease — mechanisms and70%
mentions🧫Sirtuin Dysfunction Validation in Parkinson's Disease70%
mentions🧫Sirtuin Pathway Dysfunction Validation in Parkinson's D70%
mentions🧫Sleep and Circadian Dysfunction as Driver of Neurodegenerati70%
mentions🧫Sleep Disruption and Alzheimer's Disease — mechanism an70%
mentions🧫Sleep and Respiratory Network Interaction in ALS — Experimen70%
mentions🧫Stress Granule Dysfunction Validation in Parkinson's Di70%
mentions🧫Synaptic Mitochondrial Resilience Enhancement for Parkinson&70%
mentions🧫Synaptic Vesicle Trafficking Dysfunction Validation in Parki70%
mentions🧫Tau Pathology Initiation Zone Identification70%
mentions🧫Tau PET Pattern as Therapeutic Response Predictor in 4R-Tauo70%
mentions🧫Tau Propagation Causality Test — Does Tau Spread Drive Neuro70%
mentions🧫Traumatic Brain Injury and Alzheimer's Disease Relation70%
mentions🧫Biomechanical Impact Profiles and Chronic Traumatic Encephal70%
mentions🧫TDP-43 PET Ligand Development for FTD and ALS70%
mentions🧫TMEM106B Haplotype as Genetic Modifier in FTD — Mechanism an70%
mentions🧫Tau ASO Therapy70%
mentions🧫TREM2 Function in Alzheimer's Disease — From Risk Varia70%
mentions🧫Vascular Contribution to Alzheimer's Disease — Beyond A70%
mentions🧫Vascular Contributions to Alzheimer Disease and Mixed Pathol70%
mentions🧫Viral Infections and Alzheimer's Disease — causal mecha70%
mentions🧫Viral and Post-Infectious Mechanisms in ALS — Experiment Des70%
mentions🧫Wilson Disease Neurodegeneration: Mechanism and Therapeutic 70%
related🧫ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De70%
related🧫Macroautophagy Dysfunction in PD - Experiment Design70%
related🧫ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De70%
related🧫Macroautophagy Dysfunction in PD - Experiment Design70%
related🧫GWAS of plasma pTau217 in East Asian cohort63%
related🧫KEEPS Continuation: Long-term effects of menopausal hormone 63%
related🧫s:** - Compare brain penetration in FcRn+/+ vs FcRn-/- mice 63%
related🧫s:** - Biochemical binding assays measuring PROTAC selectivi63%
related🧫CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs 63%
related🧫4R-Tau Targeting Therapies for PSP and CBS63%
related🧫AAV-LRRK2 IND-Enabling Study Design63%
related🧫AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Posi63%
related🧫Alpha-Synuclein SAA Kinetics Study — Biological Staging Back63%
related🧫Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio63%
related🧫Computational Modeling of Alpha-Synuclein Propagation in PD63%
related🧫Basic Mechanism: Membrane-Driven Alpha-Synuclein Nucleation63%
related🧫Alpha-Synuclein Seed Amplification Assay Validation63%
related🧫Alpha-Synuclein Spreading Mechanism — Prion-Like Propagation63%
related🧫Metabolic Pathway-Targeted Therapy in ALS63%
related🧫ALS Progression Rate Heterogeneity — mechanism and biomarker63%
related🧫ALS Regional Onset and Spread: Network-Level Staging Model63%
related🧫Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk63%
related🧫Why Does Amyloid Removal Only Slow Decline 27%? — Mechanisti63%
related🧫Mechanism: Why Does Amyloid Removal Only Slow Decline 27%?63%
related🧫Animal Model Comparison for Neurodegenerative Disease Therap63%
related🧫Anti-Tau Immunotherapy Dosing Optimization63%
related🧫Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri63%
related🧫Antiviral Therapy Trial for Parkinson's Disease63%
related🧫Astrocyte Ferritin Iron Metabolism Dysfunction in Parkinson&63%
related🧫Experiment: Autoimmune Hypothesis Testing in AD63%
related🧫Autophagy Enhancement Drug Screening for Neurodegeneration63%
related🧫Axonal Transport Dysfunction Validation in Parkinson's 63%
related🧫Biomarker-Guided Sequential Therapy Selection in Alzheimer&#63%
related🧫Blood-Based Biomarker Panel for Early AD Detection63%
related🧫Blood Biomarker vs Tau PET for Treatment Monitoring63%
related🧫tACS Connectivity Trial in Early Alzheimer's63%
related🧫Brain Connectivity-Targeted tACS Trial in Early AD63%
related🧫Brainstem Circuit Modulation for PSP63%
related🧫Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT63%
related🧫C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study63%
related🧫Experimental: CAAR-T Cell Therapy for Autoantibody-Mediated 63%
related🧫cGAS-STING Pathway Validation Study in Parkinson's Dise63%
related🧫Chaperone-Mediated Autophagy Dysfunction in PD - Experiment 63%
related🧫Cognitive Reserve Mechanisms in Alzheimer's Disease — M63%
related🧫Combination Therapy Sequencing in Parkinson's Disease63%
related🧫CRISPR Gene Correction Approaches for CBS/PSP63%
related🧫Cholinergic System Dysfunction in DLB — Mechanisms and Thera63%
related🧫DLB Cognitive Fluctuation Mechanism Experiment63%
related🧫Genetic Risk Modifiers in DLB Phenotype63%
related🧫Tau Co-Pathology in DLB Clinical Heterogeneity63%
related🧫DLB Treatment Response Biomarkers — Predicting Cholinesteras63%
related🧫DNA Damage Repair Deficiency Validation Study in Parkinson&#63%
related🧫Mechanism: Selective Vulnerability of Dopaminergic Neurons i63%
related🧫Down Syndrome Alzheimer's Disease: Mechanisms and Thera63%
related🧫Endocannabinoid System Dysfunction Validation in Parkinson&#63%
related🧫Environmental Exposure Causal Attribution in ALS — Experimen63%
related🧫Epigenetic Clocks in Neurodegeneration — Causal Drivers or P63%
related🧫Epigenetic Dysregulation in Huntington's Disease — Ther63%
related🧫Epigenetic Dysregulation Validation in Parkinson's Dise63%
related🧫Epigenetic Regulation Dysfunction in Alzheimer's and Pa63%
related🧫Exercise-BDNF-Mitophagy Biomarker Study in PD63%
related🧫Experiment Index63%
related🧫Ferroptosis Validation in Parkinson's Disease63%
related🧫Frontal and Temporal Lobe Selective Vulnerability in FTD — M63%
related🧫FTD Microglia Role: Protective vs Destructive Mechanism Stud63%
related🧫FTLD-Tau vs FTLD-TDP In Vivo Biomarker Differentiation63%
related🧫FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio63%
related🧫Gap Junction Dysfunction Validation in Parkinson's Dise63%
related🧫GLP-1 Agonist Neuroprotection Mechanism in PD63%
related🧫GLP-1 Agonist Responder Prediction Study — Precision Medicin63%
related🧫Glymphatic-Circadian Axis Enhancement Therapy for Parkinson&63%
related🧫Gut-Brain Axis Pathogenesis in Parkinson's Disease — Me63%
related🧫Iron Dyshomeostasis in MSA Pathogenesis Experiment63%
related🧫Levodopa-Induced Dyskinesias Mechanism — Experiment Design63%
related🧫Levodopa Response Determinants in PSP — Biomarker-Guided Pre63%
related🧫Cytochrome Therapeutics63%
related🧫Lipid Droplet-Lysosome Axis Therapeutic Testing in Parkinson63%
related🧫AAV-LRRK2 Gene Therapy IND-Enabling Study Design63%
related🧫LRRK2/GBA Mutation Carrier Resilience — Why Some Carriers Ne63%
related🧫Validate Mitochondria-Lysosome Contact Site Dysfunction in P63%
related🧫Validation: Membrane-Nucleation in iPSC Neurons63%
related🧫Metabolic Syndrome-Parkinson's Disease Axis Clinical Tr63%
related🧫Metal Ion Homeostasis Dysregulation in Alzheimer's Dise63%
related🧫Experiment Design: Metal Ion-Synuclein-Mitochondria Axis in 63%
related🧫Mutant Huntingtin (mHTT) Clearance Mechanisms — Therapeutic 63%
related🧫Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag63%
related🧫Microbiome-Gut Barrier Signatures in ALS — Experiment Design63%
related🧫Microbiome-Gut-Brain Axis in Alzheimer's Disease — mech63%
related🧫Microglial Aging and Immune Memory in Neurodegeneration — Tr63%
related🧫Microglial Contributions to Huntington's Disease Pathog63%
related🧫Migraine Cortical Hyperexcitability and Alzheimer's Dis63%
related🧫Mixed Pathology Effects on Parkinson's Disease Progress63%
related🧫MLCS Quantification in Parkinson's Disease63%
related🧫Experiment: Multi-Ethnic PD GWAS63%
related🧫Multiscale Computational Modeling of Protein Aggregation Kin63%
related🧫N-of-1 Clinical Trial Design for CBS/PSP63%
related🧫Neural Oscillation Dysfunction Validation in Parkinson'63%
related🧫Neural Stem Cell Therapy for Alzheimer's Disease63%
related🧫NLRP3 Inflammasome Validation Study in Parkinson's Dise63%
related🧫Non-Dopaminergic Neurotransmitter Degeneration in PD - Exper63%
related🧫Non-Motor Symptom Progression in Parkinson's Disease — 63%
related🧫Normal Aging to Alzheimer's Disease Transition Trigger 63%
related🧫CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs 63%
related🧫NPH Glymphatic System Interaction Experiment63%
related🧫Oligodendrocyte-Myelin Dysfunction Validation in Parkinson&#63%
related🧫Parkinson's Disease Subtype Classification — Precision 63%
related🧫Peroxisomal Dysfunction Validation in Parkinson's Disea63%
related🧫Peroxisome Dysfunction Validation in Parkinson's Diseas63%
related🧫Pre-Symptomatic Tau Detection in MAPT Mutation Carriers63%
related🧫Presymptomatic GRN Carrier Intervention Timing — Biomarker-G63%
related🧫Pre-Symptomatic Detection and Intervention Timing in Genetic63%
related🧫Prion Strain Diversity and Selective Vulnerability in CJD63%
related🧫Prodromal Parkinson's Disease Biomarker Development — E63%
related🧫Progranulin Replacement Therapy for FTD — Vector Development63%
related🧫Mechanism: Progranulin Loss and TDP-43 Pathology in FTD63%
related🧫Proteasome-Ubiquitin System Dysfunction Validation in Parkin63%
related🧫PSP and CBS Biomarker Validation Study63%
related🧫Purinergic Signaling Dysfunction Validation in Parkinson63%
related🧫Regulated Necrosis Validation Study in Parkinson's Dise63%
related🧫Spinocerebellar Ataxia (SCA) Disease-Modifying Therapy Devel63%
related🧫SCFA-Mediated Neuroinflammation in Alzheimer's Disease63%
related🧫Experiment Scoring Methodology63%
related🧫Selective Neuronal Vulnerability to Aging — Mapping Why Spec63%
related🧫Senolytic Therapy (D+Q) Phase IIa Trial in Early Alzheimer&#63%
related🧫Sex Differences in Alzheimer's Disease — mechanisms and63%
related🧫Sirtuin Dysfunction Validation in Parkinson's Disease63%
related🧫Sirtuin Pathway Dysfunction Validation in Parkinson's D63%
related🧫Sleep and Circadian Dysfunction as Driver of Neurodegenerati63%
related🧫Sleep Disruption and Alzheimer's Disease — mechanism an63%
related🧫Sleep and Respiratory Network Interaction in ALS — Experimen63%
related🧫Stress Granule Dysfunction Validation in Parkinson's Di63%
related🧫Synaptic Mitochondrial Resilience Enhancement for Parkinson&63%
related🧫Synaptic Vesicle Trafficking Dysfunction Validation in Parki63%
related🧫Tau Pathology Initiation Zone Identification63%
related🧫Tau PET Pattern as Therapeutic Response Predictor in 4R-Tauo63%
related🧫Tau Propagation Causality Test — Does Tau Spread Drive Neuro63%
related🧫Traumatic Brain Injury and Alzheimer's Disease Relation63%
related🧫Biomechanical Impact Profiles and Chronic Traumatic Encephal63%
related🧫TDP-43 PET Ligand Development for FTD and ALS63%
related🧫TMEM106B Haplotype as Genetic Modifier in FTD — Mechanism an63%
related🧫Tau ASO Therapy63%
related🧫TREM2 Function in Alzheimer's Disease — From Risk Varia63%
related🧫Vascular Contribution to Alzheimer's Disease — Beyond A63%
related🧫Vascular Contributions to Alzheimer Disease and Mixed Pathol63%
related🧫Viral Infections and Alzheimer's Disease — causal mecha63%
related🧫Viral and Post-Infectious Mechanisms in ALS — Experiment Des63%
related🧫Wilson Disease Neurodegeneration: Mechanism and Therapeutic 63%
related🔬What are the mechanisms underlying autophagy-lysosome pathwa50%
related🔬What are the mechanisms underlying protein aggregation cross50%
related🔬Is disrupted sleep a cause or consequence of neurodegenerati50%
related🔬Is disrupted sleep a cause or consequence of neurodegenerati50%
related🔬What gene expression changes in the aging mouse brain predic50%
related🔬What gene expression changes in the aging mouse brain predic50%
related🔬What gene expression changes in the aging mouse brain predic50%
related🔬What gene expression changes in the aging mouse brain predic50%
related🔬What gene expression changes in the aging mouse brain predic50%
related🔬How does metabolic reprogramming (glucose metabolism shifts,50%
related🔬Can speech, gait, retinal imaging, sleep, and smartphone dat50%
mentions🔬Can speech, gait, retinal imaging, sleep, and smartphone dat40%
mentions🔬What are the mechanisms underlying autophagy-lysosome pathwa40%
mentions🔬What are the mechanisms underlying protein aggregation cross40%
mentions🔬Is disrupted sleep a cause or consequence of neurodegenerati40%
mentions🔬Is disrupted sleep a cause or consequence of neurodegenerati40%
mentions🔬What gene expression changes in the aging mouse brain predic40%
mentions🔬What gene expression changes in the aging mouse brain predic40%
mentions🔬What gene expression changes in the aging mouse brain predic40%
mentions🔬What gene expression changes in the aging mouse brain predic40%
mentions🔬What gene expression changes in the aging mouse brain predic40%
mentions🔬How does metabolic reprogramming (glucose metabolism shifts,40%
SciDEX — scidex.ai — Dashboard | Mission Control | Status | How it Works | GitHub